Gemini Therapeutics (GMTX) Competitors $69.28 +1.50 (+2.21%) As of 10/6/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrendsBuy This Stock GMTX vs. ROIV, MRNA, ELAN, QGEN, BBIO, VRNA, RVMD, MRUS, GRFS, and RYTMShould you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include Roivant Sciences (ROIV), Moderna (MRNA), Elanco Animal Health (ELAN), Qiagen (QGEN), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Revolution Medicines (RVMD), Merus (MRUS), Grifols (GRFS), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. Gemini Therapeutics vs. Its Competitors Roivant Sciences Moderna Elanco Animal Health Qiagen BridgeBio Pharma Verona Pharma PLC American Depositary Share Revolution Medicines Merus Grifols Rhythm Pharmaceuticals Gemini Therapeutics (NASDAQ:GMTX) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk. Which has more volatility & risk, GMTX or ROIV? Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Does the media refer more to GMTX or ROIV? In the previous week, Roivant Sciences had 5 more articles in the media than Gemini Therapeutics. MarketBeat recorded 5 mentions for Roivant Sciences and 0 mentions for Gemini Therapeutics. Roivant Sciences' average media sentiment score of 0.67 beat Gemini Therapeutics' score of 0.00 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Overall Sentiment Gemini Therapeutics Neutral Roivant Sciences Positive Do analysts recommend GMTX or ROIV? Roivant Sciences has a consensus target price of $19.94, indicating a potential upside of 23.68%. Given Roivant Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Roivant Sciences is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Roivant Sciences 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.80 Which has higher earnings and valuation, GMTX or ROIV? Gemini Therapeutics has higher earnings, but lower revenue than Roivant Sciences. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGemini TherapeuticsN/AN/A-$71.87M-$1.00-69.28Roivant Sciences$29.05M378.93-$171.98M-$0.70-23.03 Is GMTX or ROIV more profitable? Gemini Therapeutics has a net margin of 0.00% compared to Roivant Sciences' net margin of -2,111.79%. Roivant Sciences' return on equity of -15.90% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gemini TherapeuticsN/A -38.78% -35.88% Roivant Sciences -2,111.79%-15.90%-14.95% Do insiders and institutionals believe in GMTX or ROIV? 75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryRoivant Sciences beats Gemini Therapeutics on 12 of the 16 factors compared between the two stocks. Get Gemini Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GMTX vs. The Competition Export to ExcelMetricGemini TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.00B$1.05B$6.10B$10.53BDividend YieldN/A4.84%5.51%4.66%P/E Ratio-69.281.2885.6826.85Price / SalesN/A30.43584.82185.94Price / CashN/A17.6426.3031.10Price / Book23.977.6513.256.72Net Income-$71.87M-$7.66M$3.30B$276.44M7 Day Performance6.49%30.55%4.70%3.13%1 Month Performance14.02%32.68%8.43%10.21%1 Year Performance38.75%73.53%88.01%40.35% Gemini Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GMTXGemini TherapeuticsN/A$69.28+2.2%N/A+35.8%$3.00BN/A-69.2830ROIVRoivant Sciences3.5032 of 5 stars$15.21+0.7%$19.94+31.1%+42.9%$10.40B$23.23M-21.75860MRNAModerna4.3215 of 5 stars$25.70+1.5%$41.81+62.7%-54.3%$10.03B$3.24B-3.425,800ELANElanco Animal Health2.5853 of 5 stars$19.99+1.9%$18.33-8.3%+41.1%$9.93B$4.44B23.249,000News CoverageAnalyst UpgradeGap UpQGENQiagen4.4532 of 5 stars$44.61+1.5%$49.69+11.4%+10.9%$9.92B$1.98B26.375,765BBIOBridgeBio Pharma4.2779 of 5 stars$51.67-0.6%$63.94+23.8%+116.4%$9.89B$221.90M-12.65400VRNAVerona Pharma PLC American Depositary Share1.87 of 5 stars$106.63+0.0%$109.00+2.2%+234.0%$9.19B$42.28M-107.7030Positive NewsRVMDRevolution Medicines4.2767 of 5 stars$46.25+0.4%$74.64+61.4%-1.6%$8.66B$11.58M-10.29250MRUSMerus1.1162 of 5 stars$93.98+0.3%$92.88-1.2%+82.1%$7.11B$36.13M-17.0937Analyst DowngradeGap UpHigh Trading VolumeGRFSGrifols3.7614 of 5 stars$10.02+0.9%$10.30+2.8%+7.7%$6.89B$7.81B8.5623,822Short Interest ↑RYTMRhythm Pharmaceuticals3.5455 of 5 stars$101.22+0.6%$106.64+5.4%+97.2%$6.73B$130.13M-33.68140 Related Companies and Tools Related Companies Roivant Sciences Alternatives Moderna Alternatives Elanco Animal Health Alternatives Qiagen Alternatives BridgeBio Pharma Alternatives Verona Pharma PLC American Depositary Share Alternatives Revolution Medicines Alternatives Merus Alternatives Grifols Alternatives Rhythm Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GMTX) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
